Science Applications International Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Science Applications International Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $7.26B | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $7.48B | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | $7.44B | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | $7.70B | Mar 17, 2025 |
| FY2018 | Feb 2, 2018 | $1.13B | Mar 29, 2018 |
| FY2018 | Nov 3, 2017 | $1.15B | Mar 29, 2018 |
| FY2018 | Aug 4, 2017 | $1.08B | Mar 29, 2018 |
| FY2018 | May 5, 2017 | $1.10B | Mar 29, 2018 |
| FY2018 | Feb 3, 2017 | $1.02B | Mar 29, 2018 |
| FY2018 | Nov 4, 2016 | $1.11B | Mar 29, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $7.26B | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $7.48B | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | $7.44B | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | $7.70B | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | $7.39B | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | $7.06B | Apr 3, 2023 |
| FY2020 | Jan 31, 2020 | $1.54B | Mar 27, 2020 |
| FY2020 | Nov 1, 2019 | $1.63B | Mar 27, 2020 |
| FY2020 | Aug 2, 2019 | $1.59B | Mar 27, 2020 |
| FY2020 | May 3, 2019 | $1.62B | Mar 27, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 31, 2025 | $362.00M | Mar 17, 2025 |
| FY2025 | Feb 2, 2024 | $477.00M | Mar 17, 2025 |
| FY2025 | Feb 3, 2023 | $300.00M | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | $277.00M | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | $209.00M | Apr 3, 2023 |
| FY2020 | Jan 31, 2020 | $60.00M | Mar 27, 2020 |
| FY2020 | Nov 1, 2019 | $56.00M | Mar 27, 2020 |
| FY2020 | Aug 2, 2019 | $57.00M | Mar 27, 2020 |
| FY2020 | May 3, 2019 | $56.00M | Mar 27, 2020 |
| FY2020 | Feb 1, 2019 | ($9.00M) | Mar 27, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $521.00M | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $563.00M | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | $741.00M | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | $501.00M | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | $462.00M | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | $390.00M | Apr 3, 2023 |
| FY2020 | Jan 31, 2020 | $88.00M | Mar 27, 2020 |
| FY2020 | Nov 1, 2019 | $94.00M | Mar 27, 2020 |
| FY2020 | Aug 2, 2019 | $95.00M | Mar 27, 2020 |
| FY2020 | May 3, 2019 | $93.00M | Mar 27, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $13.00M | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $12.00M | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | $4.00M | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | $1.00M | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | $4.00M | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | $6.00M | Apr 3, 2023 |
| FY2022 | Jan 31, 2020 | $7.00M | Mar 28, 2022 |
| FY2021 | Feb 1, 2019 | $5.00M | Mar 26, 2021 |
| FY2020 | Feb 2, 2018 | $4.00M | Mar 27, 2020 |
| FY2019 | Feb 3, 2017 | $4.00M | Mar 29, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $350.00M | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $339.00M | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | $373.00M | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | $374.00M | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | $344.00M | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | $352.00M | Apr 3, 2023 |
| FY2022 | Jan 31, 2020 | $288.00M | Mar 28, 2022 |
| FY2021 | Feb 1, 2019 | $158.00M | Mar 26, 2021 |
| FY2020 | Feb 2, 2018 | $155.00M | Mar 27, 2020 |
| FY2019 | Feb 3, 2017 | $166.00M | Mar 29, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $609.00M | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $494.00M | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | $396.00M | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | $532.00M | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | $518.00M | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | $755.00M | Apr 3, 2023 |
| FY2022 | Jan 31, 2020 | $458.00M | Mar 28, 2022 |
| FY2021 | Feb 1, 2019 | $184.00M | Mar 26, 2021 |
| FY2020 | Feb 2, 2018 | $217.00M | Mar 27, 2020 |
| FY2019 | Feb 3, 2017 | $273.00M | Mar 29, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $32.00M | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $36.00M | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | $27.00M | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | $25.00M | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | $36.00M | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | $46.00M | Apr 3, 2023 |
| FY2022 | Jan 31, 2020 | $21.00M | Mar 28, 2022 |
| FY2021 | Feb 1, 2019 | $28.00M | Mar 26, 2021 |
| FY2020 | Feb 2, 2018 | $22.00M | Mar 27, 2020 |
| FY2019 | Feb 3, 2017 | $15.00M | Mar 29, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $5.35B | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $5.25B | Mar 16, 2026 |
| FY2025 | Feb 2, 2024 | $5.31B | Mar 17, 2025 |
| FY2024 | Feb 3, 2023 | $5.54B | Mar 20, 2024 |
| FY2023 | Jan 28, 2022 | $5.75B | Apr 3, 2023 |
| FY2022 | Jan 29, 2021 | $5.72B | Mar 28, 2022 |
| FY2021 | Jan 31, 2020 | $4.71B | Mar 26, 2021 |
| FY2020 | Feb 1, 2019 | $4.56B | Mar 27, 2020 |
| FY2019 | Feb 2, 2018 | $2.07B | Mar 29, 2019 |
| FY2018 | Feb 3, 2017 | $2.04B | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $1.50B | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $1.58B | Mar 16, 2026 |
| FY2025 | Feb 2, 2024 | $1.79B | Mar 17, 2025 |
| FY2024 | Feb 3, 2023 | $1.69B | Mar 20, 2024 |
| FY2023 | Jan 28, 2022 | $1.62B | Apr 3, 2023 |
| FY2022 | Jan 29, 2021 | $1.54B | Mar 28, 2022 |
| FY2021 | Jan 31, 2020 | $1.42B | Mar 26, 2021 |
| FY2020 | Feb 1, 2019 | $1.49B | Mar 27, 2020 |
| FY2019 | Feb 2, 2018 | $327.00M | Mar 29, 2019 |
| FY2018 | Feb 3, 2017 | $349.00M | Mar 29, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $2.94B | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $2.85B | Mar 16, 2026 |
| FY2025 | Feb 2, 2024 | $2.85B | Mar 17, 2025 |
| FY2024 | Feb 3, 2023 | $2.91B | Mar 20, 2024 |
| FY2023 | Jan 28, 2022 | $2.91B | Apr 3, 2023 |
| FY2022 | Jan 29, 2021 | $2.79B | Mar 28, 2022 |
| FY2021 | Jan 31, 2020 | $2.14B | Mar 26, 2021 |
| FY2020 | Feb 1, 2019 | $2.12B | Mar 27, 2020 |
| FY2019 | Feb 2, 2018 | $863.00M | Mar 29, 2019 |
| FY2018 | Feb 3, 2017 | $863.00M | Mar 29, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $1.49B | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $1.57B | Mar 16, 2026 |
| FY2025 | Feb 2, 2024 | $1.43B | Mar 17, 2025 |
| FY2024 | Feb 3, 2023 | $1.04B | Mar 20, 2024 |
| FY2023 | Jan 28, 2022 | $818.00M | Apr 3, 2023 |
| FY2022 | Jan 29, 2021 | $627.00M | Mar 28, 2022 |
| FY2021 | Jan 31, 2020 | $506.00M | Mar 26, 2021 |
| FY2020 | Feb 1, 2019 | $367.00M | Mar 27, 2020 |
| FY2019 | Feb 3, 2018 | $326.00M | Mar 29, 2019 |
| FY2019 | Feb 2, 2018 | $323.00M | Mar 29, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $182.00M | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $56.00M | Mar 16, 2026 |
| FY2025 | Feb 2, 2024 | $94.00M | Mar 17, 2025 |
| FY2024 | Feb 3, 2023 | $109.00M | Mar 20, 2024 |
| FY2023 | Jan 28, 2022 | $106.00M | Apr 3, 2023 |
| FY2022 | Jan 29, 2021 | $171.00M | Mar 28, 2022 |
| FY2021 | Jan 31, 2020 | $188.00M | Mar 26, 2021 |
| FY2020 | Feb 1, 2019 | $237.00M | Mar 27, 2020 |
| FY2019 | Feb 2, 2018 | $144.00M | Mar 29, 2019 |
| FY2018 | Feb 3, 2017 | $210.00M | Mar 29, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $2.49B | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $2.22B | Mar 16, 2026 |
| FY2025 | Feb 2, 2024 | $2.10B | Mar 17, 2025 |
| FY2024 | Feb 3, 2023 | $2.37B | Mar 20, 2024 |
| FY2023 | Jan 28, 2022 | $2.52B | Apr 3, 2023 |
| FY2022 | Jan 29, 2021 | $2.52B | Mar 28, 2022 |
| FY2021 | Jan 31, 2020 | $1.92B | Mar 26, 2021 |
| FY2020 | Feb 1, 2019 | $2.09B | Mar 27, 2020 |
| FY2019 | Feb 2, 2018 | $1.02B | Mar 29, 2019 |
| FY2018 | Feb 3, 2017 | $1.05B | Mar 29, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | 7 | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | 7 | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | 8 | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | 5 | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | 4 | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | 3 | Apr 3, 2023 |
| FY2020 | Jan 31, 2020 | 1 | Mar 27, 2020 |
| FY2020 | Nov 1, 2019 | 0 | Mar 27, 2020 |
| FY2020 | Aug 2, 2019 | 0 | Mar 27, 2020 |
| FY2020 | May 3, 2019 | 0 | Mar 27, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | 7 | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | 7 | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | 8 | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | 5 | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | 4 | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | 3 | Apr 3, 2023 |
| FY2020 | Jan 31, 2020 | 1 | Mar 27, 2020 |
| FY2020 | Nov 1, 2019 | 0 | Mar 27, 2020 |
| FY2020 | Aug 2, 2019 | 0 | Mar 27, 2020 |
| FY2020 | May 3, 2019 | 0 | Mar 27, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | 44.00M | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | 48.00M | Mar 16, 2026 |
| FY2025 | Feb 2, 2024 | 52.00M | Mar 17, 2025 |
| FY2024 | Feb 3, 2023 | 54.00M | Mar 20, 2024 |
| FY2023 | Jan 28, 2022 | 56.00M | Apr 3, 2023 |
| FY2022 | Jan 29, 2021 | 58.00M | Mar 28, 2022 |
| FY2021 | Jan 31, 2020 | 58.00M | Mar 26, 2021 |
| FY2020 | Feb 1, 2019 | 60.00M | Mar 27, 2020 |
| FY2019 | Feb 2, 2018 | 43.00M | Mar 29, 2019 |
| FY2018 | Feb 3, 2017 | 44.00M | Mar 29, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2026 | Jan 30, 2026 | $70.00M | Mar 16, 2026 |
| FY2026 | Jan 31, 2025 | $75.00M | Mar 16, 2026 |
| FY2026 | Feb 2, 2024 | $79.00M | Mar 16, 2026 |
| FY2025 | Feb 3, 2023 | $83.00M | Mar 17, 2025 |
| FY2024 | Jan 28, 2022 | $86.00M | Mar 20, 2024 |
| FY2023 | Jan 29, 2021 | $87.00M | Apr 3, 2023 |
| FY2022 | Jan 31, 2020 | $87.00M | Mar 28, 2022 |
| FY2021 | Feb 1, 2019 | $53.00M | Mar 26, 2021 |
| FY2020 | Feb 2, 2018 | $54.00M | Mar 27, 2020 |
| FY2019 | Feb 3, 2017 | $54.00M | Mar 29, 2019 |